<DOC>
	<DOCNO>NCT02778763</DOCNO>
	<brief_summary>Double blind , randomize , placebo-controlled , multicenter pilot study efficacy safety CBLB612 follow single administration neutropenia prophylaxis breast cancer patient receive doxorubicin cyclophosphamide myelosuppressive chemotherapy</brief_summary>
	<brief_title>Study Efficacy Safety CBLB612 Neutropenia Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>1 . Written inform consent study participation . 2 . Women age 18 year inclusively . 3 . Patients histologically proven diagnosis breast cancer 1st cycle AC chemotherapy treatment indicate ( 3week interval ) . 4 . ECOG Performance Status 02 . 5 . Life expectancy ≥ 6 month . 6 . Completion previous cancer therapy ( include surgery , radiotherapy , chemotherapy , immunotherapy study therapy ) later 4 week prior CBLB612 study . 7 . All acute toxic effect previous therapy &lt; Grade 1 prior study , except alopecia and/or neurotoxicity ( Grade 1 2 allow ) . 8 . Adequate hematopoiesis function : WBC ≥3.0 x 103/μl ; PTT ≥1.5 x 103/μl ; Platelets ≥75 x 103/μl ; Hemoglobin ≥10 g/dl . 9 . Adequate hepatic function : Total bilirubin ≤1.5 x ULN ; ALT AST ≤3 x ULN ; Alkaline phosphatase ≤2.5 x ULN . 10 . Adequate renal function : Creatinine ≤1.5 x ULN . 11 . Adequate value hemostasis system : Prothrombin time ; ≤1.5 x ULN ; Activated partial thromboplastin time ≤1.5 x ULN ; INR ≤1.5 x ULN . 12 . Adequate cardiac function mean LVEF ≥45 base ultrasonic examination heart radionuclide angiography ; 12lead electrocardiogram ( ECG ) normal tracing , nonclinically significant change may occur require medical intervention . 13 . Negative test serological infection marker : Negative HIVantibody test ; Negative test hepatitis B surface antigen ( HBsAg ) ; Negative test hepatitis C virus antibody negative test mRNA hepatitis C virus ; Negative test Treponema pallidum antibody . 14 . Negative pregnancy test . 15 . Consent patient preserve reproductive function use effective contraception method since screen least 3 month study therapy . e.g . intrauterine device , oral contraceptive , subcutaneous implant doublebarrier method ( condom contraceptive sponge contraceptive vaginal suppository ) . 16 . A patient shall ready able meet requirement study protocol opportunity participate study throughout scheduled period . 1 . Rapidly progress , clinically unstable breast cancer present clinical sign cerebral meningeal membrane metastasis . 2 . Specific contraindication hypersensitivity data relation follow drug : doxorubicin , cyclophosphamide , CBLB612 , antiemetic agent ( aprepitant , palonosetron ) , antiinflammatory drug ( include paracetamol aspirin ) , well excipients abovementioned drug agent include polysorbate 80 . 3 . History febrile neutropenia . 4 . Presence autoimmune disease . 5 . Acute chronic/relapsing inflammatory eye disease significant eye disorder . patient mild moderate myopia hypermetropia , presbyopia may enrol study . 6 . Pregnancy breast feeding , refusal use adequate contraception method study . 7 . Signs ongoing systemic bacterial , fungal viral infectious disease local infection require treatment randomization . patient local fungal lesion skin area nail may enrol study . 8 . Systemic antibiotic therapy 72 hour prior randomization . 9 . Previous radiotherapy ≥30 % bone marrow . 10 . Surgery chemotherapy experimental drug therapy within 4 week prior randomization . 11 . Transplantation bone marrow peripheral blood precursor cell . 12 . Intake 10 portion alcoholic beverage per week anamnestic data alcoholism , narcomania , drug abuse . one portion alcoholic beverage 250 ml beer , 125 ml wine 30 ml strong alcoholic beverage . 13 . Current immunosuppressant therapy include systemic corticosteroid therapy . 14 . Clinically significant abnormal vital sign , result laboratory instrumental test , base investigator assessment . 15 . Any disease , condition , organ dysfunction central nervous system disorder intake narcotic drug , accord investigator , may affect ability participate study hinder assessment study result .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>TLR2</keyword>
	<keyword>Neutropenia</keyword>
</DOC>